Industry Research Reports
Home > Reports > Chemical & Material > Global Pharmaceutical Grade Poloxamer 407 Market Outlook, In‑Depth Analysis & Forecast to 2031
Global Pharmaceutical Grade Poloxamer 407 Market Outlook, In‑Depth Analysis & Forecast to 2031
Industry: Chemical & Material
Published Date: 2025-10-03
Pages: 119 Pages
Report ld: 5120579
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
The global Pharmaceutical Grade Poloxamer 407 market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Poloxamer 407, also known as Pluronic F127, is a nonionic triblock copolymer composed of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) units. It is commonly used in pharmaceuticals, cosmetics, and other industries for its unique properties.Poloxamer 407 is a surfactant and emulsifying agent that can stabilize emulsions and improve the solubility of poorly soluble drugs. It has a hydrophilic PEO segment that provides water solubility and a hydrophobic PPO segment that contributes to its surfactant properties. This combination allows Poloxamer 407 to form micelles in aqueous solutions, which can encapsulate hydrophobic substances and improve their dispersibility.
From a downstream perspective, Topical Formulations accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Pharmaceutical Grade Poloxamer 407 leading manufacturers including BASF, Croda, CD Formulation, Comercial Química Massó, Solvay, etc., dominate supply; the top five capture approximately % of global revenue, with BASF leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Pharmaceutical Grade Poloxamer 407 market, seamlessly integrating production capacity and sales performance across the value chain. It analyzes historical production, revenue, and sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—capacity, sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- BASF
- Croda
- CD Formulation
- Comercial Química Massó
- Solvay
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Powder
- Flakes
Segment by Application
- Topical Formulations
- Solid Dosage Forms
- Oral Care Formulations
CHAPTER OUTLINE
Chapter 1: Defines the Pharmaceutical Grade Poloxamer 407 study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Maps global production capacity, utilization, and market share (2020–2031), identifies efficient hubs, reveals regulatory/trade policy impacts and bottlenecks.
Chapter 4: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 5: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 6: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 7: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 8: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 9: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 10: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 11: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 12: Profiles manufacturers in depth—details product specs, capacity, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 13: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint and technology, cost drivers, plus downstream channels and distributor roles.
Chapter 14: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 7–11) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 13) and customers (Chapter 6) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 4 and 12).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 13 and 14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Pharmaceutical Grade Poloxamer 407: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Pharmaceutical Grade Poloxamer 407 Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Powder
1.2.3 Flakes
1.3 Market Segmentation by Application
1.3.1 Global Pharmaceutical Grade Poloxamer 407 Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Topical Formulations
1.3.3 Solid Dosage Forms
1.3.4 Oral Care Formulations
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Pharmaceutical Grade Poloxamer 407 Revenue Estimates and Forecasts 2020-2031
2.2 Global Pharmaceutical Grade Poloxamer 407 Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Pharmaceutical Grade Poloxamer 407 Sales Estimates and Forecasts 2020-2031
2.4 Global Pharmaceutical Grade Poloxamer 407 Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Global Production Analysis
3.1 Global Pharmaceutical Grade Poloxamer 407 Production Capacity and Utilization Rates (2020–2031)
3.2 Regional Production: Comparative Analysis (2020 VS 2024 VS 2031)
3.3 Regional Production Dynamics
3.3.1 Historic Production by Region (2020-2025)
3.3.2 Forecasted Production by Region (2026-2031)
3.3.3 Production Market Share by Region (2020-2031)
3.3.4 Regulatory and Trade Policy Impact on Production
3.3.5 Production Capacity Enablers and Constraints
3.4 Key Regional Production Hubs
3.4.1 North America
3.4.2 Europe
3.4.3 China
4 Competition by Manufacturers
4.1 Global Pharmaceutical Grade Poloxamer 407 Sales by Manufacturers
4.1.1 Global Sales Volume by Manufacturers (2020-2025)
4.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
4.2 Global Pharmaceutical Grade Poloxamer 407 Manufacturer Revenue Rankings and Tiers
4.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
4.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
4.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
4.3 Manufacturer Profitability Profiles and Pricing Strategies
4.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
4.3.2 Manufacturer-Level Price Trends (2020-2025)
4.4 Key Manufacturers Manufacturing Base and Headquarters
4.5 Main Product Type Market Size by Manufacturers
4.5.1 Powder Market Size by Manufacturers
4.5.2 Flakes Market Size by Manufacturers
4.6 Global Pharmaceutical Grade Poloxamer 407 Market Concentration and Dynamics
4.6.1 Global Market Concentration (CR5 and HHI)
4.6.2 Entrant/Exit Impact Analysis
4.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
5 Global Product Segmentation Analysis
5.1 Global Pharmaceutical Grade Poloxamer 407 Sales Performance by Type
5.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
5.1.2 Global Sales Market Share by Type (2020-2031)
5.2 Global Pharmaceutical Grade Poloxamer 407 Revenue Trends by Type
5.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
5.2.2 Global Revenue Market Share by Type (2020-2031)
5.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
5.4 Product Technology Differentiation
5.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
5.5.1 High-Growth Niches and Adoption Drivers
5.5.2 Profitability Hotspots and Cost Drivers
5.5.3 Substitution Threats
6 Global Downstream Application Analysis
6.1 Global Pharmaceutical Grade Poloxamer 407 Sales by Application
6.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
6.1.2 Global Sales Market Share by Application (2020-2031)
6.1.3 High-Growth Application Identification
6.1.4 Emerging Application Case Studies
6.2 Global Pharmaceutical Grade Poloxamer 407 Revenue by Application
6.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
6.2.2 Revenue Market Share by Application (2020-2031)
6.3 Global Pricing Dynamics by Application (2020-2031)
6.4 Downstream Customer Analysis
6.4.1 Top Customers by Region
6.4.2 Top Customers by Application
7 North America
7.1 North America Sales Volume and Revenue (2020-2031)
7.2 North America Key Manufacturers Sales Revenue in 2024
7.3 North America Pharmaceutical Grade Poloxamer 407 Sales and Revenue by Type (2020-2031)
7.4 North America Pharmaceutical Grade Poloxamer 407 Sales and Revenue by Application (2020-2031)
7.5 North America Growth Accelerators and Market Barriers
7.6 North America Pharmaceutical Grade Poloxamer 407 Market Size by Country
7.6.1 North America Revenue by Country
7.6.2 North America Sales Trends by Country
7.6.3 US
7.6.4 Canada
7.6.5 Mexico
8 Europe
8.1 Europe Sales Volume and Revenue (2020-2031)
8.2 Europe Key Manufacturers Sales Revenue in 2024
8.3 Europe Pharmaceutical Grade Poloxamer 407 Sales and Revenue by Type (2020-2031)
8.4 Europe Pharmaceutical Grade Poloxamer 407 Sales and Revenue by Application (2020-2031)
8.5 Europe Growth Accelerators and Market Barriers
8.6 Europe Pharmaceutical Grade Poloxamer 407 Market Size by Country
8.6.1 Europe Revenue by Country
8.6.2 Europe Sales Trends by Country
8.6.3 Germany
8.6.4 France
8.6.5 U.K.
8.6.6 Italy
8.6.7 Russia
9 Asia-Pacific
9.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
9.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
9.3 Asia-Pacific Pharmaceutical Grade Poloxamer 407 Sales and Revenue by Type (2020-2031)
9.4 Asia-Pacific Pharmaceutical Grade Poloxamer 407 Sales and Revenue by Application (2020-2031)
9.5 Asia-Pacific Pharmaceutical Grade Poloxamer 407 Market Size by Region
9.5.1 Asia-Pacific Revenue by Region
9.5.2 Asia-Pacific Sales Trends by Region
9.6 Asia-Pacific Growth Accelerators and Market Barriers
9.7 Southeast Asia
9.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
9.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand
9.8 China
9.9 Japan
9.10 South Korea
9.11 China Taiwan
9.12 India
10 Central and South America
10.1 Central and South America Sales Volume and Revenue (2020-2031)
10.2 Central and South America Key Manufacturers Sales Revenue in 2024
10.3 Central and South America Pharmaceutical Grade Poloxamer 407 Sales and Revenue by Type (2020-2031)
10.4 Central and South America Pharmaceutical Grade Poloxamer 407 Sales and Revenue by Application (2020-2031)
10.5 Central and South America Investment Opportunities and Key Challenges
10.6 Central and South America Pharmaceutical Grade Poloxamer 407 Market Size by Country
10.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 Brazil
10.6.3 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
11.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
11.3 Middle East and Africa Pharmaceutical Grade Poloxamer 407 Sales and Revenue by Type (2020-2031)
11.4 Middle East and Africa Pharmaceutical Grade Poloxamer 407 Sales and Revenue by Application (2020-2031)
11.5 Middle East and Africa Investment Opportunities and Key Challenges
11.6 Middle East and Africa Pharmaceutical Grade Poloxamer 407 Market Size by Country
11.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
11.6.2 GCC Countries
11.6.3 Turkey
11.6.4 Egypt
11.6.5 South Africa
12 Corporate Profile
12.1 BASF
12.1.1 BASF Corporation Information
12.1.2 BASF Business Overview
12.1.3 BASF Pharmaceutical Grade Poloxamer 407 Product Models, Descriptions and Specifications
12.1.4 BASF Pharmaceutical Grade Poloxamer 407 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.1.5 BASF Pharmaceutical Grade Poloxamer 407 Sales by Product in 2024
12.1.6 BASF Pharmaceutical Grade Poloxamer 407 Sales by Application in 2024
12.1.7 BASF Pharmaceutical Grade Poloxamer 407 Sales by Geographic Area in 2024
12.1.8 BASF Pharmaceutical Grade Poloxamer 407 SWOT Analysis
12.1.9 BASF Recent Developments
12.2 Croda
12.2.1 Croda Corporation Information
12.2.2 Croda Business Overview
12.2.3 Croda Pharmaceutical Grade Poloxamer 407 Product Models, Descriptions and Specifications
12.2.4 Croda Pharmaceutical Grade Poloxamer 407 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.2.5 Croda Pharmaceutical Grade Poloxamer 407 Sales by Product in 2024
12.2.6 Croda Pharmaceutical Grade Poloxamer 407 Sales by Application in 2024
12.2.7 Croda Pharmaceutical Grade Poloxamer 407 Sales by Geographic Area in 2024
12.2.8 Croda Pharmaceutical Grade Poloxamer 407 SWOT Analysis
12.2.9 Croda Recent Developments
12.3 CD Formulation
12.3.1 CD Formulation Corporation Information
12.3.2 CD Formulation Business Overview
12.3.3 CD Formulation Pharmaceutical Grade Poloxamer 407 Product Models, Descriptions and Specifications
12.3.4 CD Formulation Pharmaceutical Grade Poloxamer 407 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.3.5 CD Formulation Pharmaceutical Grade Poloxamer 407 Sales by Product in 2024
12.3.6 CD Formulation Pharmaceutical Grade Poloxamer 407 Sales by Application in 2024
12.3.7 CD Formulation Pharmaceutical Grade Poloxamer 407 Sales by Geographic Area in 2024
12.3.8 CD Formulation Pharmaceutical Grade Poloxamer 407 SWOT Analysis
12.3.9 CD Formulation Recent Developments
12.4 Comercial Química Massó
12.4.1 Comercial Química Massó Corporation Information
12.4.2 Comercial Química Massó Business Overview
12.4.3 Comercial Química Massó Pharmaceutical Grade Poloxamer 407 Product Models, Descriptions and Specifications
12.4.4 Comercial Química Massó Pharmaceutical Grade Poloxamer 407 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.4.5 Comercial Química Massó Pharmaceutical Grade Poloxamer 407 Sales by Product in 2024
12.4.6 Comercial Química Massó Pharmaceutical Grade Poloxamer 407 Sales by Application in 2024
12.4.7 Comercial Química Massó Pharmaceutical Grade Poloxamer 407 Sales by Geographic Area in 2024
12.4.8 Comercial Química Massó Pharmaceutical Grade Poloxamer 407 SWOT Analysis
12.4.9 Comercial Química Massó Recent Developments
12.5 Solvay
12.5.1 Solvay Corporation Information
12.5.2 Solvay Business Overview
12.5.3 Solvay Pharmaceutical Grade Poloxamer 407 Product Models, Descriptions and Specifications
12.5.4 Solvay Pharmaceutical Grade Poloxamer 407 Capacity, Sales, Price, Revenue and Gross Margin (2020-2025)
12.5.5 Solvay Pharmaceutical Grade Poloxamer 407 Sales by Product in 2024
12.5.6 Solvay Pharmaceutical Grade Poloxamer 407 Sales by Application in 2024
12.5.7 Solvay Pharmaceutical Grade Poloxamer 407 Sales by Geographic Area in 2024
12.5.8 Solvay Pharmaceutical Grade Poloxamer 407 SWOT Analysis
12.5.9 Solvay Recent Developments
13 Value Chain and Supply-Chain Analysis
13.1 Pharmaceutical Grade Poloxamer 407 Industry Chain
13.2 Pharmaceutical Grade Poloxamer 407 Upstream Materials Analysis
13.2.1 Raw Materials
13.2.2 Key Suppliers Market Share & Risk Assessment
13.3 Pharmaceutical Grade Poloxamer 407 Integrated Production Analysis
13.3.1 Manufacturing Footprint Analysis
13.3.2 Production Technology Overview
13.3.3 Regional Cost Drivers
13.4 Pharmaceutical Grade Poloxamer 407 Sales Channels and Distribution Networks
13.4.1 Sales Channels
13.4.2 Distributors
14 Pharmaceutical Grade Poloxamer 407 Market Dynamics
14.1 Industry Trends and Evolution
14.2 Market Growth Drivers and Emerging Opportunities
14.3 Market Challenges, Risks, and Restraints
15 Key Findings in the Global Pharmaceutical Grade Poloxamer 407 Study
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.1.1 Research Programs/Design
16.1.1.2 Market Size Estimation
16.1.1.3 Market Breakdown and Data Triangulation
16.1.2 Data Source
16.1.2.1 Secondary Sources
16.1.2.2 Primary Sources
16.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Pharmaceutical Grade Poloxamer 407 Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Pharmaceutical Grade Poloxamer 407 Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Pharmaceutical Grade Poloxamer 407 Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Pharmaceutical Grade Poloxamer 407 Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Pharmaceutical Grade Poloxamer 407 Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Pharmaceutical Grade Poloxamer 407 Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)
Table 7. Global Pharmaceutical Grade Poloxamer 407 Sales by Region (2020-2025) & (Tons)
Table 8. Global Pharmaceutical Grade Poloxamer 407 Sales by Region (2026-2031) & (Tons)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Pharmaceutical Grade Poloxamer 407 Production Growth Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)
Table 11. Global Pharmaceutical Grade Poloxamer 407 Production by Region (2020-2025) & (Tons)
Table 12. Global Pharmaceutical Grade Poloxamer 407 Production by Region (2026-2031) & (Tons)
Table 13. Global Pharmaceutical Grade Poloxamer 407 Sales by Manufacturers (2020-2025) & (Tons)
Table 14. Global Pharmaceutical Grade Poloxamer 407 Sales Share by Manufacturers (2020-2025)
Table 15. Global Pharmaceutical Grade Poloxamer 407 Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 16. Global Pharmaceutical Grade Poloxamer 407 Revenue Market Share by Manufacturers (2020-2025)
Table 17. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 18. Global Pharmaceutical Grade Poloxamer 407 by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmaceutical Grade Poloxamer 407 as of 2024)
Table 19. Global Pharmaceutical Grade Poloxamer 407 Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 20. Global Pharmaceutical Grade Poloxamer 407 Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Ton)
Table 21. Key Manufacturers Pharmaceutical Grade Poloxamer 407 Manufacturing Base and Headquarters
Table 22. Global Pharmaceutical Grade Poloxamer 407 Market Concentration Ratio (CR5 and HHI)
Table 23. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 24. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 25. Global Pharmaceutical Grade Poloxamer 407 Sales by Type (2020-2025) & (Tons)
Table 26. Global Pharmaceutical Grade Poloxamer 407 Sales by Type (2026-2031) & (Tons)
Table 27. Global Pharmaceutical Grade Poloxamer 407 Revenue by Type (2020-2025) & (US$ Million)
Table 28. Global Pharmaceutical Grade Poloxamer 407 Revenue by Type (2026-2031) & (US$ Million)
Table 29. Global Pharmaceutical Grade Poloxamer 407 ASP by Type (2020-2031) & (US$/Ton)
Table 30. Technical Specifications by Key Product Type
Table 31. Global Pharmaceutical Grade Poloxamer 407 Sales by Application (2020-2025) & (Tons)
Table 32. Global Pharmaceutical Grade Poloxamer 407 Sales by Application (2026-2031) & (Tons)
Table 33. Pharmaceutical Grade Poloxamer 407 High-Growth Sectors Demand CAGR (2024-2031)
Table 34. Global Pharmaceutical Grade Poloxamer 407 Revenue by Application (2020-2025) & (US$ Million)
Table 35. Global Pharmaceutical Grade Poloxamer 407 Revenue by Application (2026-2031) & (US$ Million)
Table 36. Global Pharmaceutical Grade Poloxamer 407 ASP by Application (2020-2031) & (US$/Ton)
Table 37. Top Customers by Region
Table 38. Top Customers by Application
Table 39. North America Pharmaceutical Grade Poloxamer 407 Growth Accelerators and Market Barriers
Table 40. North America Pharmaceutical Grade Poloxamer 407 Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 41. North America Pharmaceutical Grade Poloxamer 407 Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 42. Europe Pharmaceutical Grade Poloxamer 407 Growth Accelerators and Market Barriers
Table 43. Europe Pharmaceutical Grade Poloxamer 407 Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 44. Europe Pharmaceutical Grade Poloxamer 407 Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 45. Asia-Pacific Pharmaceutical Grade Poloxamer 407 Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Asia-Pacific Pharmaceutical Grade Poloxamer 407 Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 47. Asia-Pacific Pharmaceutical Grade Poloxamer 407 Growth Accelerators and Market Barriers
Table 48. Southeast Asia Pharmaceutical Grade Poloxamer 407 Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 49. Central and South America Pharmaceutical Grade Poloxamer 407 Investment Opportunities and Key Challenges
Table 50. Central and South America Pharmaceutical Grade Poloxamer 407 Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 51. Middle East and Africa Pharmaceutical Grade Poloxamer 407 Investment Opportunities and Key Challenges
Table 52. Middle East and Africa Pharmaceutical Grade Poloxamer 407 Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 53. BASF Corporation Information
Table 54. BASF Description and Major Businesses
Table 55. BASF Product Models, Descriptions and Specifications
Table 56. BASF Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 57. BASF Sales Value Proportion by Product in 2024
Table 58. BASF Sales Value Proportion by Application in 2024
Table 59. BASF Sales Value Proportion by Geographic Area in 2024
Table 60. BASF Pharmaceutical Grade Poloxamer 407 SWOT Analysis
Table 61. BASF Recent Developments
Table 62. Croda Corporation Information
Table 63. Croda Description and Major Businesses
Table 64. Croda Product Models, Descriptions and Specifications
Table 65. Croda Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 66. Croda Sales Value Proportion by Product in 2024
Table 67. Croda Sales Value Proportion by Application in 2024
Table 68. Croda Sales Value Proportion by Geographic Area in 2024
Table 69. Croda Pharmaceutical Grade Poloxamer 407 SWOT Analysis
Table 70. Croda Recent Developments
Table 71. CD Formulation Corporation Information
Table 72. CD Formulation Description and Major Businesses
Table 73. CD Formulation Product Models, Descriptions and Specifications
Table 74. CD Formulation Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 75. CD Formulation Sales Value Proportion by Product in 2024
Table 76. CD Formulation Sales Value Proportion by Application in 2024
Table 77. CD Formulation Sales Value Proportion by Geographic Area in 2024
Table 78. CD Formulation Pharmaceutical Grade Poloxamer 407 SWOT Analysis
Table 79. CD Formulation Recent Developments
Table 80. Comercial Química Massó Corporation Information
Table 81. Comercial Química Massó Description and Major Businesses
Table 82. Comercial Química Massó Product Models, Descriptions and Specifications
Table 83. Comercial Química Massó Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 84. Comercial Química Massó Sales Value Proportion by Product in 2024
Table 85. Comercial Química Massó Sales Value Proportion by Application in 2024
Table 86. Comercial Química Massó Sales Value Proportion by Geographic Area in 2024
Table 87. Comercial Química Massó Pharmaceutical Grade Poloxamer 407 SWOT Analysis
Table 88. Comercial Química Massó Recent Developments
Table 89. Solvay Corporation Information
Table 90. Solvay Description and Major Businesses
Table 91. Solvay Product Models, Descriptions and Specifications
Table 92. Solvay Capacity, Sales (Tons), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2020-2025)
Table 93. Solvay Sales Value Proportion by Product in 2024
Table 94. Solvay Sales Value Proportion by Application in 2024
Table 95. Solvay Sales Value Proportion by Geographic Area in 2024
Table 96. Solvay Pharmaceutical Grade Poloxamer 407 SWOT Analysis
Table 97. Solvay Recent Developments
Table 98. Key Raw Materials Distribution
Table 99. Raw Materials Key Suppliers
Table 100. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 101. Milestones in Production Technology Evolution
Table 102. Distributors List
Table 103. Market Trends and Market Evolution
Table 104. Market Drivers and Opportunities
Table 105. Market Challenges, Risks, and Restraints
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
List of Figures
Figure 1. Pharmaceutical Grade Poloxamer 407 Product Picture
Figure 2. Global Pharmaceutical Grade Poloxamer 407 Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Powder Product Picture
Figure 4. Flakes Product Picture
Figure 5. Global Pharmaceutical Grade Poloxamer 407 Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Topical Formulations
Figure 7. Solid Dosage Forms
Figure 8. Oral Care Formulations
Figure 9. Pharmaceutical Grade Poloxamer 407 Report Years Considered
Figure 10. Global Pharmaceutical Grade Poloxamer 407 Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Pharmaceutical Grade Poloxamer 407 Revenue (2020-2031) & (US$ Million)
Figure 12. Global Pharmaceutical Grade Poloxamer 407 Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Pharmaceutical Grade Poloxamer 407 Revenue Market Share by Region (2020-2031)
Figure 14. Global Pharmaceutical Grade Poloxamer 407 Sales (2020-2031) & (Tons)
Figure 15. Global Pharmaceutical Grade Poloxamer 407 Sales (CAGR) by Region (2020-2031) (Tons)
Figure 16. Global Pharmaceutical Grade Poloxamer 407 Sales Market Share by Region (2020-2031)
Figure 17. Global Pharmaceutical Grade Poloxamer 407 Capacity, Production and Utilization (2020-2031) & (Tons)
Figure 18. Global Pharmaceutical Grade Poloxamer 407 Production Trend by Region (2020-2031) (Tons)
Figure 19. Global Pharmaceutical Grade Poloxamer 407 Production Market Share by Region (2020-2031)
Figure 20. Production Capacity Enablers & Constraints
Figure 21. Pharmaceutical Grade Poloxamer 407 Production Growth Rate in North America (2020-2031) & (Tons)
Figure 22. Pharmaceutical Grade Poloxamer 407 Production Growth Rate in Europe (2020-2031) & (Tons)
Figure 23. Pharmaceutical Grade Poloxamer 407 Production Growth Rate in China (2020-2031) & (Tons)
Figure 24. Top 5 and Top 10 Manufacturers Pharmaceutical Grade Poloxamer 407 Sales Volume Market Share in 2024
Figure 25. Global Pharmaceutical Grade Poloxamer 407 Revenue Market Share Ranking (2024)
Figure 26. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 27. Powder Revenue Market Share by Manufacturer in 2024
Figure 28. Flakes Revenue Market Share by Manufacturer in 2024
Figure 29. Type Eight Revenue Market Share by Manufacturer in 2024
Figure 30. Type Nine Revenue Market Share by Manufacturer in 2024
Figure 31. Global Pharmaceutical Grade Poloxamer 407 Sales Market Share by Type (2020-2031)
Figure 32. Global Pharmaceutical Grade Poloxamer 407 Revenue Market Share by Type (2020-2031)
Figure 33. Global Pharmaceutical Grade Poloxamer 407 Sales Market Share by Application (2020-2031)
Figure 34. Global Pharmaceutical Grade Poloxamer 407 Revenue Market Share by Application (2020-2031)
Figure 35. North America Pharmaceutical Grade Poloxamer 407 Sales YoY (2020-2031) & (Tons)
Figure 36. North America Pharmaceutical Grade Poloxamer 407 Revenue YoY (2020-2031) & (US$ Million)
Figure 37. North America Top 5 Manufacturers Pharmaceutical Grade Poloxamer 407 Sales Revenue (US$ Million) in 2024
Figure 38. North America Pharmaceutical Grade Poloxamer 407 Sales Volume (Tons) by Type (2020- 2031)
Figure 39. North America Pharmaceutical Grade Poloxamer 407 Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 40. North America Pharmaceutical Grade Poloxamer 407 Sales Volume (Tons) by Application (2020-2031)
Figure 41. North America Pharmaceutical Grade Poloxamer 407 Sales Revenue (US$ Million) by Application (2020-2031)
Figure 42. US Pharmaceutical Grade Poloxamer 407 Revenue (2020-2031) & (US$ Million)
Figure 43. Canada Pharmaceutical Grade Poloxamer 407 Revenue (2020-2031) & (US$ Million)
Figure 44. Mexico Pharmaceutical Grade Poloxamer 407 Revenue (2020-2031) & (US$ Million)
Figure 45. Europe Pharmaceutical Grade Poloxamer 407 Sales YoY (2020-2031) & (Tons)
Figure 46. Europe Pharmaceutical Grade Poloxamer 407 Revenue YoY (2020-2031) & (US$ Million)
Figure 47. Europe Top 5 Manufacturers Pharmaceutical Grade Poloxamer 407 Sales Revenue (US$ Million) in 2024
Figure 48. Europe Pharmaceutical Grade Poloxamer 407 Sales Volume (Tons) by Type (2020-2031)
Figure 49. Europe Pharmaceutical Grade Poloxamer 407 Sales Revenue (US$ Million) by Type (2020-2031)
Figure 50. Europe Pharmaceutical Grade Poloxamer 407 Sales Volume (Tons) by Application (2020-2031)
Figure 51. Europe Pharmaceutical Grade Poloxamer 407 Sales Revenue (US$ Million) by Application (2020-2031)
Figure 52. Germany Pharmaceutical Grade Poloxamer 407 Revenue (2020-2031) & (US$ Million)
Figure 53. France Pharmaceutical Grade Poloxamer 407 Revenue (2020-2031) & (US$ Million)
Figure 54. U.K. Pharmaceutical Grade Poloxamer 407 Revenue (2020-2031) & (US$ Million)
Figure 55. Italy Pharmaceutical Grade Poloxamer 407 Revenue (2020-2031) & (US$ Million)
Figure 56. Russia Pharmaceutical Grade Poloxamer 407 Revenue (2020-2031) & (US$ Million)
Figure 57. Asia-Pacific Pharmaceutical Grade Poloxamer 407 Sales YoY (2020-2031) & (Tons)
Figure 58. Asia-Pacific Pharmaceutical Grade Poloxamer 407 Revenue YoY (2020-2031) & (US$ Million)
Figure 59. Asia-Pacific Top 8 Manufacturers Pharmaceutical Grade Poloxamer 407 Sales Revenue (US$ Million) in 2024
Figure 60. Asia-Pacific Pharmaceutical Grade Poloxamer 407 Sales Volume (Tons) by Type (2020- 2031)
Figure 61. Asia-Pacific Pharmaceutical Grade Poloxamer 407 Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 62. Asia-Pacific Pharmaceutical Grade Poloxamer 407 Sales Volume (Tons) by Application (2020-2031)
Figure 63. Asia-Pacific Pharmaceutical Grade Poloxamer 407 Sales Revenue (US$ Million) by Application (2020-2031)
Figure 64. Indonesia Pharmaceutical Grade Poloxamer 407 Revenue (2020-2031) & (US$ Million)
Figure 65. Japan Pharmaceutical Grade Poloxamer 407 Revenue (2020-2031) & (US$ Million)
Figure 66. South Korea Pharmaceutical Grade Poloxamer 407 Revenue (2020-2031) & (US$ Million)
Figure 67. China Taiwan Pharmaceutical Grade Poloxamer 407 Revenue (2020-2031) & (US$ Million)
Figure 68. India Pharmaceutical Grade Poloxamer 407 Revenue (2020-2031) & (US$ Million)
Figure 69. Central and South America Pharmaceutical Grade Poloxamer 407 Sales YoY (2020-2031) & (Tons)
Figure 70. Central and South America Pharmaceutical Grade Poloxamer 407 Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Central and South America Top 5 Manufacturers Pharmaceutical Grade Poloxamer 407 Sales Revenue (US$ Million) in 2024
Figure 72. Central and South America Pharmaceutical Grade Poloxamer 407 Sales Volume (Tons) by Type (2021-2031)
Figure 73. Central and South America Pharmaceutical Grade Poloxamer 407 Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Central and South America Pharmaceutical Grade Poloxamer 407 Sales Volume (Tons) by Application (2020-2031)
Figure 75. Central and South America Pharmaceutical Grade Poloxamer 407 Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. Brazil Pharmaceutical Grade Poloxamer 407 Revenue (2020-2025) & (US$ Million)
Figure 77. Argentina Pharmaceutical Grade Poloxamer 407 Revenue (2020-2025) & (US$ Million)
Figure 78. Middle East, and Africa Pharmaceutical Grade Poloxamer 407 Sales YoY (2020-2031) & (Tons)
Figure 79. Middle East and Africa Pharmaceutical Grade Poloxamer 407 Revenue YoY (2020-2031) & (US$ Million)
Figure 80. Middle East and Africa Top 5 Manufacturers Pharmaceutical Grade Poloxamer 407 Sales Revenue (US$ Million) in 2024
Figure 81. Middle East and Africa Pharmaceutical Grade Poloxamer 407 Sales Volume (Tons) by Type (2021-2031)
Figure 82. South America Pharmaceutical Grade Poloxamer 407 Sales Revenue (US$ Million) by Type (2020-2031)
Figure 83. Middle East and Africa Pharmaceutical Grade Poloxamer 407 Sales Volume (Tons) by Application (2020-2031)
Figure 84. Middle East and Africa Pharmaceutical Grade Poloxamer 407 Sales Revenue (US$ Million) by Application (2020-2031)
Figure 85. GCC Countries Pharmaceutical Grade Poloxamer 407 Revenue (2020-2025) & (US$ Million)
Figure 86. Turkey Pharmaceutical Grade Poloxamer 407 Revenue (2020-2025) & (US$ Million)
Figure 87. Egypt Pharmaceutical Grade Poloxamer 407 Revenue (2020-2025) & (US$ Million)
Figure 88. South Africa Pharmaceutical Grade Poloxamer 407 Revenue (2020-2025) & (US$ Million)
Figure 89. Pharmaceutical Grade Poloxamer 407 Industry Chain Mapping
Figure 90. Regional Pharmaceutical Grade Poloxamer 407 Manufacturing Base Distribution (%)
Figure 91. Pharmaceutical Grade Poloxamer 407 Production Process
Figure 92. Regional Pharmaceutical Grade Poloxamer 407 Production Cost Structure
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which companies rank high in the global Pharmaceutical Grade Poloxamer 407 market?
The top companies in the global Pharmaceutical Grade Poloxamer 407 market are BASF、Croda、CD Formulation.
Related Reports
Global Pharmaceutical Grade Poloxamer 407 Market Research Report 2026
The global Pharmaceutical Grade Poloxamer 407 market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-02-02
Pages: 118
USD 2900.00
(Single User License)
Pharmaceutical Grade Poloxamer 407- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Pharmaceutical Grade Poloxamer 407 was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-02-02
Pages: 84
USD 3950.00
(Single User License)
Global Pharmaceutical Grade Poloxamer 407 Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Pharmaceutical Grade Poloxamer 407 market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-14
Pages: 69
USD 4250.00
(Single User License)
Pharmaceutical Grade Poloxamer 407- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Pharmaceutical Grade Poloxamer 407 was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-14
Pages: 81
USD 3950.00
(Single User License)
Global Pharmaceutical Grade Poloxamer 407 Market Research Report 2025
The global market for Pharmaceutical Grade Poloxamer 407 was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-02-14
Pages: 80
USD 2900.00
(Single User License)
Global Pharmaceutical Grade Poloxamer 407 Market Insights, Forecast to 2030
Poloxamer 407, also known as Pluronic F127, is a nonionic triblock copolymer composed of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) units. It is commonly used in pharmaceuticals, cosmetics, and other industries for its unique properties.Poloxamer 407 is a surfactant and emulsifying agent that can stabilize emulsions and improve the solubility of poorly soluble drugs. It has a hydrophilic PEO segment that provides water solubility and a hydrophobic PPO segment that contributes to its surfactant properties. This combination allows Poloxamer 407 to form micelles in aqueous solutions, which can encapsulate hydrophobic substances and improve their dispersibility.
Published Date: 2024-04-26
Pages: 91
USD 4900.00
(Single User License)
Global Pharmaceutical Grade Poloxamer 407 Market Research Report 2024
Poloxamer 407, also known as Pluronic F127, is a nonionic triblock copolymer composed of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) units. It is commonly used in pharmaceuticals, cosmetics, and other industries for its unique properties.Poloxamer 407 is a surfactant and emulsifying agent that can stabilize emulsions and improve the solubility of poorly soluble drugs. It has a hydrophilic PEO segment that provides water solubility and a hydrophobic PPO segment that contributes to its surfactant properties. This combination allows Poloxamer 407 to form micelles in aqueous solutions, which can encapsulate hydrophobic substances and improve their dispersibility.
Published Date: 2024-01-20
Pages: 88
USD 2900.00
(Single User License)
Global Pharmaceutical Grade Poloxamer 407 Market Research Report 2026
The global Pharmaceutical Grade Poloxamer 407 market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-02-02
Pages: 118
USD 2900.00 (Single User License)Pharmaceutical Grade Poloxamer 407- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Pharmaceutical Grade Poloxamer 407 was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-02-02
Pages: 84
USD 3950.00 (Single User License)Global Pharmaceutical Grade Poloxamer 407 Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Pharmaceutical Grade Poloxamer 407 market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-14
Pages: 69
USD 4250.00 (Single User License)Pharmaceutical Grade Poloxamer 407- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Pharmaceutical Grade Poloxamer 407 was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-14
Pages: 81
USD 3950.00 (Single User License)Global Pharmaceutical Grade Poloxamer 407 Market Research Report 2025
The global market for Pharmaceutical Grade Poloxamer 407 was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-02-14
Pages: 80
USD 2900.00 (Single User License)Global Pharmaceutical Grade Poloxamer 407 Market Insights, Forecast to 2030
Poloxamer 407, also known as Pluronic F127, is a nonionic triblock copolymer composed of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) units. It is commonly used in pharmaceuticals, cosmetics, and other industries for its unique properties.Poloxamer 407 is a surfactant and emulsifying agent that can stabilize emulsions and improve the solubility of poorly soluble drugs. It has a hydrophilic PEO segment that provides water solubility and a hydrophobic PPO segment that contributes to its surfactant properties. This combination allows Poloxamer 407 to form micelles in aqueous solutions, which can encapsulate hydrophobic substances and improve their dispersibility.
Published: 2024-04-26
Pages: 91
USD 4900.00 (Single User License)Global Pharmaceutical Grade Poloxamer 407 Market Research Report 2024
Poloxamer 407, also known as Pluronic F127, is a nonionic triblock copolymer composed of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) units. It is commonly used in pharmaceuticals, cosmetics, and other industries for its unique properties.Poloxamer 407 is a surfactant and emulsifying agent that can stabilize emulsions and improve the solubility of poorly soluble drugs. It has a hydrophilic PEO segment that provides water solubility and a hydrophobic PPO segment that contributes to its surfactant properties. This combination allows Poloxamer 407 to form micelles in aqueous solutions, which can encapsulate hydrophobic substances and improve their dispersibility.
Published: 2024-01-20
Pages: 88
USD 2900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now